By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Markets > Iveric Bio Agrees to $5.9 Billion Bid From Astellas. The Stock Is Surging.
Markets

Iveric Bio Agrees to $5.9 Billion Bid From Astellas. The Stock Is Surging.

News Room
Last updated: 2023/05/01 at 1:32 PM
By News Room
Share
2 Min Read
SHARE

Astellas Pharma
said Monday that it agreed to acquire Iveric Bio for around $5.9 billion. It’s the largest ever acquisition for Japan’s Astellas, underlining competition for acquisitions in growth areas such as ophthalmology. 

Biopharmaceuticals have been a relatively busy area for deals this year compared with a general slowdown in mergers and acquisitions in the U.S. 

Astellas
(ticker: 4503.Japan) said
Iveric
(ISEE) has promising programs and capabilities in the field of ophthalmology, including a potential treatment for geographic atrophy, an advanced form of age-related macular degeneration. 

Astellas also said the deal would provide future revenue which would help compensate for the expected decline in sales of its Xtandi prostate-cancer drug later this decade, due to the expiration of its patent.

Astellas said it would pay $40 a share for Iveric. Shares in Iveric were up 18% at $38.79 in premarket trading on Monday. Astellas shares closed up 2.2% in Japan. 

“The opportunity to create a world-class entity with the ophthalmology expertise and capabilities of Iveric Bio and the global reach and resources of Astellas is unique and has the potential to benefit patients worldwide suffering from blinding retinal diseases,” Iveric President Pravin Dugel said in a joint statement from the companies.

Write to Adam Clark at adam.clark@barrons.com

Read the full article here

News Room May 1, 2023 May 1, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Elon Musk says he will spend a ‘lot less’ on politics

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

EU to impose €2 tax on low-cost items in blow to Temu and Shein

Stay informed with free updatesSimply sign up to the EU trade myFT…

Microsoft-backed UK tech unicorn Builder.ai collapses into insolvency

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Trumpism’s growing split: Bannon vs plutocrats

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

Israel’s Gaza aid plan could lead to ‘war crime’, UN agency chief says

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

- Advertisement -
Ad imageAd image

You Might Also Like

Crypto

'Fundamental Shift' in Traditional Bitcoin Market Cycle May Be on the Horizon

By News Room
Crypto

FTX/Alameda Unstakes Over $1B in Solana – Is a Major Price Shift Coming?

By News Room
Crypto

Mastercard Launches “Crypto Credential” To Replace Wallet Addresses With Usernames

By News Room
Crypto

Polygon Executive Pivots Roles To Developing ZK Proof Tech

By News Room
Crypto

Altcoin Interest Driving South Korean Crypto Craze – Report

By News Room
Crypto

Russian Central Bank Flags Sharp Rise in Crypto-related Activity

By News Room
Crypto

BitGo’s $100M Suit Against Galaxy Gets Green Light from Delaware Supreme Court

By News Room
Crypto

Here Are Your Top Crypto Gainers Today on DEXScreener

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?